Legend Biotech/$LEGN
1D1W1MYTD1Y5YMAX
Capital at risk
About Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
- Ticker
- $LEGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,200
- Headquarters
- Somerset, United States
- Website
- legendbiotech.com
Legend Biotech Metrics
BasicAdvanced
$3.4B
-
-$0.50
0.39
-
Price and volume
Market cap
$3.4B
Beta
0.39
52-week high
$37.50
52-week low
$16.24
Average daily volume
2.1M
Financial strength
Current ratio
3.041
Quick ratio
2.881
Long term debt to equity
0.089
Total debt to equity
0.226
Interest coverage (TTM)
-2.24%
Profitability
EBITDA (TTM)
-41.6
Gross margin (TTM)
56.58%
Net profit margin (TTM)
-7.20%
Operating margin (TTM)
-4.15%
Effective tax rate (TTM)
-62.81%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
-1.92%
Return on equity (TTM)
-8.08%
Valuation
Price to revenue (TTM)
2.576
Price to book
2.78
Price to tangible book (TTM)
2.78
Price to free cash flow (TTM)
-24.628
Free cash flow yield (TTM)
-4.06%
Free cash flow per share (TTM)
-0.717
Growth
Revenue change (TTM)
59.55%
Earnings per share change (TTM)
-71.88%
3-year revenue growth (CAGR)
97.65%
3-year earnings per share growth (CAGR)
-46.04%
What the Analysts think about Legend Biotech
Analyst ratings (Buy, Hold, Sell) for Legend Biotech stock.
Analyst projections of the future price of Legend Biotech stock.
Bulls say / Bears say
Legend Biotech reported Q1 FY26 revenue of $305.1 million, up 56% year-over-year, with collaboration revenue climbing 61% and Carvykti net trade sales rising 62% to $597 million (SEC).
Its investigational in vivo CAR-T therapy LB2501 achieved a 100% objective response rate and 83% complete response rate in the higher-dose cohort of its Phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma, demonstrating promising pipeline diversification (Nasdaq).
The company held $834.6 million in cash and time deposits as of March 31, 2026, securing financial runway beyond 2026 to fund operations and pipeline advancement (SEC).
Despite narrowing, the net loss remained $54.3 million in Q1 FY26, indicating ongoing unprofitability (SEC).
Collaboration revenue of $298.4 million accounted for nearly 98% of total revenue in Q1 FY26, highlighting heavy reliance on Carvykti under the Janssen agreement (SEC).
Cost of collaboration revenue surged by $105.9 million, driven by manufacturing capacity expansion and depreciation charges, pressuring near-term margins (SEC).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Legend Biotech Financial Performance
Revenues and expenses
Legend Biotech Earnings Performance
Company profitability
Upcoming events
No upcoming events
Legend Biotech News
AllArticlesVideos
Legend Biotech taps Novartis veteran Zhang as CEO
Reuters1 day ago
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
WSJ1 day ago
Legend Biotech Q2 Earnings Call Highlights
MarketBeat1 month ago
Funds containing Legend Biotech
AllUSDGBPEUR
Fund name | Fund size | $LEGN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.11% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.11% |
iShares MSCI China€ICGA | €2.3B | 0.05% |
SPDR MSCI EM Asia$EMAD | $1.7B | 0.01% |
SPDR MSCI EM Asia€SPYA | €1.4B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.